Eluforsen

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameEluforsen
Drug Alias NameAntisense oligonucleotide targeting the F508delta mutation of CFTR - ProQR TherapeuticsQR-10QR-010
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionCystic fibrosis transmembrane conductance regulator modulators
TargetsCystic fibrosis transmembrane conductance regulator
Therapy Area/IndicationsCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[10] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesProqr Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesProqr Therapeutics
Active IndicationsN/A
Inactive IndicationsCystic Fibrosis

Other Information

ATC CodeN/A
Related LinksN/A